CAMP4 Therapeutics Corporation

Stage 4 · Declining · week 11→4 today

As of Oct 22, 2026, CAMP4 Therapeutics is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $3.39, 52.5% below its 52-week high and below its 200-day average, which is falling.

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. More about the company

$3.39

+3.04% today

$213M · Micro cap

Market Neutral — Fading

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CAMP early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-10-11 → 2026-10-22

S? 42w

S2 17w

S4 9w

2024-10-112026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 42w → S4 6w → S1 8w → S2 17w → S3 7w → S2 4w → S3 5w → S4 9w → S1 4w → S4 1w → S1 3w → S4 1w current

Total tracked: 106 weeks across 12 stage runs.

CAMP among Biotechnology192nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…192	CAMPCAMP4 Therapeutics Corporation	Stage 4 · wk 1	53	−8.9%

vs 52W High

-52.5%

$2.90 lo$7.13 hi

52.5% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-21.0%

200 DMA: $4.29 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.49x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-8.9%

+7.3%

-23.6%

YTD

-43.5%

-0.6%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S41→4

Wk 1 · Vol 0.49x

2026-10-21S1

Wk 3 · Vol 0.60x

2026-10-20S1

Wk 3 · Vol 0.31x

2026-10-19S1

Wk 3 · Vol 0.20x

2026-10-16S1

Wk 3 · Vol 0.31x

2026-10-15S1

Wk 2 · Vol 0.19x

2026-10-14S1

Wk 2 · Vol 0.52x

2026-10-13S1

Wk 2 · Vol 0.29x

2026-10-12S1

Wk 2 · Vol 0.12x

2026-10-09S1

Wk 2 · Vol 0.24x

2026-10-08S1

Wk 1 · Vol 0.93x

2026-10-07S1

Wk 1 · Vol 0.50x

Moving averages & range

50 DMA

$4.04

200 DMA

$4.29

52W High

$7.13

52W Low

$2.90

5D Low

$3.14

Resistance levels (recent highs)

20d High

$4.04

60d High

$5.44

120d High

$5.44

250d High

$7.13

Next resistance

+19.2%

to 20d High

ROE

-545.9%

Profit margin 0.0%

Dividend Yield

0.00%

P/B -260.8

CAMP4 Therapeutics: quick answers

What stage is CAMP4 Therapeutics in?

As of Oct 22, 2026, CAMP4 Therapeutics (CAMP) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is CAMP4 Therapeutics in an uptrend?

No. CAMP4 Therapeutics is in a Stage 4 downtrend. It trades 21.0% below its 200-day average, which is falling.

How far is CAMP4 Therapeutics from its 52-week high?

CAMP4 Therapeutics closed at $3.39 on Oct 22, 2026, 52.5% below its 52-week high of $7.13. Its 52-week low is $2.90.

How has CAMP4 Therapeutics performed over the past year?

As of Oct 22, 2026, CAMP4 Therapeutics is down 0.6% over the past year and down 43.5% so far in 2026.

Which sector and industry is CAMP4 Therapeutics in?

CAMP4 Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.